The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Epilepsy Research

• Publication date

  2011-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.eplepsyres.2011.01.016PMID 21601426
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiepileptic Drug Interactions: A Clinical Guide

  2012cited by this paper
• New antiepileptic drugs

  2011cited by this paper
• Genetic basis for idiosyncratic reactions to antiepileptic drugs

  2009cited by this paper
• Population pharmacokinetics of lamotrigine in patients with epilepsy.

  2009cited by this paper
• Changes in Lamotrigine Pharmacokinetics during Pregnancy and the Puerperium

  2008cited by this paper
• Effects of pregnancy and contraception on lamotrigine disposition: new insights through analysis of lamotrigine metabolites.

  2008cited by this paper
• Smoking reduces serum levels of lamotrigine.

  2008cited by this paper
• Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII).

  2007cited by this paper
• Novel anticonvulsant drugs.

  2007cited by this paper
• Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants

  2006cited by this paper
• Pharmacokinetic Variability of Newer Antiepileptic Drugs

  2006cited by this paper
• Lack of Association between L48V Polymorphism in the UGT1A4 Gene and Lamotrigine-induced Rash

  2006cited by this paper
• The Pharmacokinetics and Interactions of New Antiepileptic Drugs: An Overview

  2005cited by this paper
• Genetic variations and haplotypes of UGT1A4 in a Japanese population.

  2005cited by this paper
• UDP-GLUCURONOSYLTRANSFERASE 1A4 POLYMORPHISMS IN A JAPANESE POPULATION AND KINETICS OF CLOZAPINE GLUCURONIDATION

  2005cited by this paper
• Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP‐glucuronosyltransferase UGT1A4

  2004cited by this paper
• Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour.

  2003cited by this paper
• Oral contraceptives reduce lamotrigine plasma levels

  2003cited by this paper
• Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs.

  2003cited by this paper
• Lamotrigine clearance during pregnancy

  2002cited by this paper
• Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.

  2002cited by this paper
• Retigabine N-glucuronidation and its potential role in enterohepatic circulation.

  1999cited by this paper
• New Antiepileptic Drugs

  1999cited by this paper
• The Clinical Pharmacokinetics of the New Antiepileptic Drugs

  1999cited by this paper
• New micromethod for the determination of lamotrigine in human plasma by high-performance liquid chromatography.

  1997cited by this paper
• Lamotrigine in Pregnancy and Lactation: A Case Report

  1997cited by this paper
• Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein.

  1996cited by this paper
• How About the New Antiepileptic Drugs?

  1994cited by this paper
• Sodium valproate acutely inhibits lamotrigine metabolism.

  1992cited by this paper

• Glutamic acid decarboxylase 65 (GAD65)-mediated autoimmune musicogenic epilepsy in a patient with acute myeloid leukaemia

  2026cites this paper
• Impact of UGT1A4 Polymorphisms on the Posaconazole Serum Trough Concentrations in Patients with Acute Myeloid Leukemia Receiving Delayed-Release Tablets.

  2025cites this paper
• Development of a PBPK Model for Lamotrigine which Incorporates Metabolism by UGT2B10: Impact of UGT2B10 Poor Metabolizer Phenotype and Pregnancy

  2025cites this paper
• Biotransformation research advances – 2024 year in review

  2025cites this paper
• PBPK Modeling of Lamotrigine and Efavirenz during Pregnancy: Implications for Personalized Dosing and Drug-Drug Interaction Management

  2024cites this paper
• Impact of UGT1A4 and UGT2B7 polymorphisms on lamotrigine plasma concentration in patients with bipolar disorder

  2024influential citation
• Lateralizing Value of Artificial Intelligence-Based Segmentation Software in MRI-Negative Focal Epilepsy

  2024cites this paper
• Influence of UGT2B7, UGT1A4 and ABCG2 Polymorphisms on the Pharmacokinetics and Therapeutic Efficacy of Lamotrigine in Patients with Epilepsy

  2024cites this paper
• UGT1A4*3 polymorphism influences serum concentration and therapeutic effect of lamotrigine for epilepsy treatment: A meta-analysis

  2024cites this paper
• Quantitative analysis of the UDP‐glucuronosyltransferase transcriptome in human tissues

  2023cites this paper
• Risk-conferring HLA variants in an epilepsy cohort: benefits of multifaceted use of whole genome sequencing in clinical practice

  2023cites this paper
• Pharmacogenetic profiling and individualised therapy in the treatment of degenerative spinal conditions

  2022cites this paper
• Effect of UGT1A4, UGT2B7, UGT2B15, UGT2B17 and ABC1B polymorphisms on lamotrigine metabolism in Danish patients.

  2022cites this paper
• Sources of Interindividual Variability.

  2021cites this paper
• The pharmacogenomics of lamotrigine (a literature review)

  2021cites this paper
• Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

  2021cites this paper
• The Evaluation of Genetic Profiles of UGT1A4 and UGT1A6 in the Turkish Population

  2021influential citation
• Evaluation of the Safety of Taking Lamotrigine During Lactation Period

  2021cites this paper
• Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors

  2020cites this paper
• How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?

  2020cites this paper
• Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies

  2020cites this paper
• The ‘collateral side’ of mood stabilizers: safety and evidence-based strategies for managing side effects

  2020cites this paper
• Sources of lamotrigine pharmacokinetic variability: A systematic review of population pharmacokinetic analyses.

  2020cites this paper
• Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy

  2020cites this paper
• PharmGKB summary: lamotrigine pathway, pharmacokinetics and pharmacodynamics

  2020cites this paper
• Psychotropic drug use in perinatal women with bipolar disorder.

  2020cites this paper
• Metabolism of Long-Acting Rilpivirine After Intramuscular Injection: HIV Prevention Trials Network Study 076 (HPTN 076)

  2020cites this paper
• Genomics and personalised medicine : diagnostics, deep phenotyping and pharmacogenomics in cohorts of rare disease patients

  2019cites this paper
• The influence of concomitant antiepileptic drugs on lamotrigine serum concentrations in Northwest Chinese Han population with epilepsy

  2019cites this paper
• Pharmacogenetics and the treatment of epilepsy: what do we know?

  2019cites this paper
• The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms.

  2019cites this paper
• Relationship Between UGT1A4 and UGT2B7 Polymorphisms and the Steady-State Plasma Concentrations of Lamotrigine in Patients With Treatment-Resistant Depressive Disorder Receiving Lamotrigine as Augmentation Therapy

  2019cites this paper
• Adjustment of the area under the concentration curve by terminal rate constant for bioequivalence assessment in a parallel‐group study of lamotrigine

  2019cites this paper
• UGT polymorphisms and lamotrigine clearance during pregnancy.

  2018cites this paper
• Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation

  2018cites this paper
• A Population Pharmacokinetic–Pharmacogenetic Model of Lamotrigine in Chinese Children With Epilepsy

  2018cites this paper
• Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update

  2018cites this paper
• Clinically Relevant Effect of UGT1A4*3 on Lamotrigine Serum Concentration Is Restricted to Postmenopausal Women—A Study Matching Therapeutic Drug Monitoring and Genotype Data From 534 Patients

  2018cites this paper
• Meta‐analysis of the Influence of UGT Genetic Polymorphisms on Lamotrigine Concentration

  2018cites this paper
• Understanding Pregnancy-induced Changes in the Disposition of Norbuprenorphine, Metformin and Glyburide in Mice and Humans for Optimizing Drug Therapy during Pregnancy

  2018cites this paper
• The effect of serum levetiracetam concentrations on therapeutic response and IL1-beta concentration in patients with epilepsy.

  2018cites this paper
• Farmacogenética de reacciones adversas a fármacos antiepilépticos

  2018cites this paper
• The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling

  2018cites this paper
• Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady‐state disposition of lamotrigine in adults with epilepsy

  2018cites this paper
• Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling

  2018cites this paper
• Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations

  2018cites this paper
• Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation

  2018cites this paper
• Analysis of Factors Influencing Plasma Lamotrigine Concentrations in Patients with Bipolar Disorder

  2017cites this paper
• Unexplained spikes in lamotrigine serum concentration: nonlinear elimination?

  2017cites this paper
• EPMA World Congress: Traditional Forum in Predictive, Preventive and Personalised Medicine for Multi-Professional Consideration and Consolidation

  2017cites this paper
• N‐glucuronidation catalyzed by UGT1A4 and UGT2B10 in human liver microsomes: Assay optimization and substrate identification

  2017cites this paper
• BIOLOGICAL MARKERS OF THE ANTIEPILEPTIC DRUGS EFFICACY AND SAFETY: PHARMACOGENETICS AND PHARMACOKINETICS

  2017cites this paper
• No association between non-bullous skin reactions from lamotrigine and heterozygosity of UGT1A4 genetic variants *2(P24T) or *3(L48V) in Norwegian patients.

  2017cites this paper
• Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.

  2016cites this paper
• Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters.

  2016cites this paper
• Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring.

  2016cites this paper
• Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy

  2016cites this paper
• Frequencies of UGT1A4*2 (P24T) and *3 (L48V) and their effects on serum concentrations of lamotrigine

  2016influential citation
• Psychiatric Pharmacogenomics: Translating Genomics

  2016cites this paper
• Analyse bio-informatique de données de séquençage de nouvelle génération pour l'étude transcriptomique d'enzymes du métabolisme

  2016cites this paper
• Glucuronidation et sulfatation du 24S-Hydroxycholestérol : rôles complémentaires dans le contrôle de l'homéostasie de ce marqueur du métabolisme neuronal

  2016cites this paper
• Association of UGT2B7 and UGT1A4 Polymorphisms with Serum Concentration of Antiepileptic Drugs in Children

  2016cites this paper
• The Impact of Pharmacokinetic Interactions With Eslicarbazepine Acetate Versus Oxcarbazepine and Carbamazepine in Clinical Practice

  2016cites this paper
• An investigation of the influence of patient‐related factors and comedications on lamotrigine clearance in patients with epilepsy

  2016cites this paper
• Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy.

  2016cites this paper
• Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy

  2016cites this paper
• Polymorphisms of ABCG2, ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy patients.

  2015cites this paper
• The pharmacogenomics of epilepsy

  2015cites this paper
• Influence of uridine diphosphate glucuronosyltransferase inducers and inhibitors on the plasma lamotrigine concentration in pediatric patients with refractory epilepsy.

  2015cites this paper
• The Polymorphic Variant P24T of UDP-Glucuronosyltransferase 1A4 and Its Unusual Consequences

  2015cites this paper
• Effects of UGT1A4 genetic polymorphisms on serum lamotrigine concentrations in Chinese children with epilepsy.

  2015cites this paper
• Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children

  2015cites this paper
• Pharmacogenetics of adverse reactions to antiepileptic drugs.

  2015cites this paper
• Découverte de nouveaux marqueurs pharmacogénomiques de la maladie du greffon contre l'hôte en transplantation de cellules souches hématopoïétiques

  2014cites this paper
• A Potential Role for Human UDP-Glucuronosyltransferase 1A4 Promoter Single Nucleotide Polymorphisms in the Pharmacogenomics of Tamoxifen and Its Derivatives

  2014cites this paper
• DMD058016 1392..1400

  2014cites this paper
• A potential role for human UDP‐glucuronosyltransferase 1A4 promoter SNPs in the pharmacogenomics of Tamoxifen and its derivatives (1141.13)

  2014cites this paper
• Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.

  2014cites this paper
• Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China

  2014cites this paper
• Pharmacogénétique des médicaments antiépileptiques

  2014cites this paper
• Sources of interindividual variability.

  2014cites this paper
• Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs

  2014cites this paper
• Farmacogenetica dei farmaci antiepilettici

  2014cites this paper
• Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations

  2013influential citation
• Prevalence of UGT1A4 and UGT2B7 polymorphismsin Thai patients

  2013influential citation
• Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function

  2013cites this paper
• Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients

  2013cites this paper
• Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients—nonlinear mixed effects modelling approach

  2013cites this paper
• Potential Role of UGT1A4 Promoter SNPs in Anastrozole Pharmacogenomics

  2013cites this paper
• Faktorer av betydning for variasjon i serumkonsentrasjonen av lamotrigin og lamotrigin 2-N-glukuronid

  2013influential citation
• Pharmacokinetic Variability of Four Newer Antiepileptic Drugs, Lamotrigine, Levetiracetam, Oxcarbazepine, and Topiramate: A Comparison of the Impact of Age and Comedication

  2012cites this paper
• Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)7TAA and UGT1A4 L48V polymorphisms

  2012cites this paper
• Association Between Lamotrigine Concentrations and ABCB1 Polymorphisms in Patients With Epilepsy

  2012cites this paper
• Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid.

  2012cites this paper
• Pharmacokinetic Variability of Olanzapine : A Study Based on Therapeutic Drug Monitoring Data

  2012cites this paper
• Methodologies used to identify and characterize interactions among antiepileptic drugs

  2012cites this paper
• UGT1A4*3 Encodes Significantly Increased Glucuronidation of Olanzapine in Patients on Maintenance Treatment and in Recombinant Systems

  2012cites this paper
• Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients.

  2012cites this paper
• Host factors affecting antiepileptic drug delivery-pharmacokinetic variability.

  2012cites this paper
• Pharmacogenomics and epilepsy: the road ahead.

  2011cites this paper